Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210


C/EBPα inhibits hepatocellular carcinoma by reducing Notch3/Hes1/p27 cascades.

Shi YC, Zhao H, Yin C, Zeng X, Zhang Q, Xu WP, Wei J, Chen F, Xie WF.

Dig Liver Dis. 2013 Oct;45(10):844-51. doi: 10.1016/j.dld.2013.03.013. Epub 2013 Jun 28.


A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.

Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM.

Hepatology. 2010 Nov;52(5):1702-12. doi: 10.1002/hep.23875.


Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice.

Zeng X, Lin Y, Yin C, Zhang X, Ning BF, Zhang Q, Zhang JP, Qiu L, Qin XR, Chen YX, Xie WF.

Hepatology. 2011 Dec;54(6):2036-47. doi: 10.1002/hep.24647.


CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle.

Wu FY, Chen H, Wang SE, ApRhys CM, Liao G, Fujimuro M, Farrell CJ, Huang J, Hayward SD, Hayward GS.

J Virol. 2003 Jan;77(2):1481-500.


CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.

Giovannini C, Gramantieri L, Minguzzi M, Fornari F, Chieco P, Grazi GL, Bolondi L.

Am J Pathol. 2012 Aug;181(2):413-22. doi: 10.1016/j.ajpath.2012.04.019. Epub 2012 Jun 15.


Decreased expression of the CCAAT/enhancer binding protein alpha gene involved in hepatocyte proliferation in human hepatocellular carcinomas.

Tomizawa M, Wang YQ, Ebara M, Saisho H, Watanabe K, Nakagawara A, Tagawa M.

Int J Mol Med. 2002 Jun;9(6):597-600.


Identification of a co-repressor that inhibits the transcriptional and growth-arrest activities of CCAAT/enhancer-binding protein alpha.

McFie PJ, Wang GL, Timchenko NA, Wilson HL, Hu X, Roesler WJ.

J Biol Chem. 2006 Jun 30;281(26):18069-80. Epub 2006 Apr 27.


CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma.

Lu GD, Ang YH, Zhou J, Tamilarasi J, Yan B, Lim YC, Srivastava S, Salto-Tellez M, Hui KM, Shen HM, Nguyen LN, Tan BC, Silver DL, Hooi SC.

Hepatology. 2015 Mar;61(3):965-78. doi: 10.1002/hep.27593. Epub 2015 Jan 30.


Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-alpha.

Wu FY, Tang QQ, Chen H, ApRhys C, Farrell C, Chen J, Fujimuro M, Lane MD, Hayward GS.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10683-8. Epub 2002 Jul 26.


CCAAT enhancer-binding protein alpha suppresses the rat placental glutathione S-transferase gene in normal liver.

Ikeda H, Omoteyama K, Yoshida K, Nishi S, Sakai M.

J Biol Chem. 2006 Mar 10;281(10):6734-41. Epub 2006 Jan 5.


Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker.

Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M.

Anticancer Res. 2003 Jan-Feb;23(1A):351-4.


The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest.

Müller C, Calkhoven CF, Sha X, Leutz A.

J Biol Chem. 2004 Feb 20;279(8):7353-8. Epub 2003 Dec 4.


Adenovirus-mediated transfer of CCAAT/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes.

Diehl AM, Johns DC, Yang S, Lin H, Yin M, Matelis LA, Lawrence JH.

J Biol Chem. 1996 Mar 29;271(13):7343-50.


Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.

Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, Kutok JL, Gilliland DG, Krauter J, Tenen DG.

Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6338-43. Epub 2006 Apr 10.


C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.

Lu GD, Leung CH, Yan B, Tan CM, Low SY, Aung MO, Salto-Tellez M, Lim SG, Hooi SC.

Gastroenterology. 2010 Aug;139(2):632-43, 643.e1-4. doi: 10.1053/j.gastro.2010.03.051. Epub 2010 Mar 27.


Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.

Jiang Y, Iakova P, Jin J, Sullivan E, Sharin V, Hong IH, Anakk S, Mayor A, Darlington G, Finegold M, Moore D, Timchenko NA.

Hepatology. 2013 Mar;57(3):1098-106. doi: 10.1002/hep.26146. Epub 2013 Feb 15.

Items per page

Supplemental Content

Write to the Help Desk